| Abstract: |
Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma. |
| Keywords: |
adult; clinical article; treatment outcome; aged; middle aged; clinical trial; disease course; diarrhea; antineoplastic agents; antineoplastic agent; metastasis; computer assisted tomography; liver toxicity; phase 2 clinical trial; anemia; tomography, x-ray computed; kidney failure; pathology; kidney carcinoma; kidney neoplasms; rash; arsenic trioxide; arsenicals; oxides; karnofsky performance status; kidney tumor; carcinoma, renal cell; disease progression; neoplasm metastasis; kidney metastasis; phase ii trial; middle age; metastatic renal cell carcinoma; organoarsenic derivative; oxide; humans; human; male; female; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|
